Europe Infectious Disease Therapeutics Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Infectious Disease Therapeutics Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Infectious Disease Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Infectious Disease Therapeutics Market Regional Analysis

6.2 Europe Infectious Disease Therapeutics Market Revenue 2020-2030 (US$ Million)

6.3 Europe Infectious Disease Therapeutics Market Forecast Analysis

7. Europe Infectious Disease Therapeutics Market Analysis – by Drug Class

7.1 Anti-viral

7.1.1 Overview
7.1.2 Anti-viral: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.2 Anti Bacterial

7.2.1 Overview
7.2.2 Anti Bacterial: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.3 Anti-Fungal

7.3.1 Overview
7.3.2 Anti-Fungal: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

8. Europe Infectious Disease Therapeutics Market Analysis – by Indication

8.1 HIV

8.1.1 Overview
8.1.2 HIV: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.2 Hepatitis

8.2.1 Overview
8.2.2 Hepatitis: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.3 Tuberculosis

8.3.1 Overview
8.3.2 Tuberculosis: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.4 Influenza

8.4.1 Overview
8.4.2 Influenza: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.5 HPV

8.5.1 Overview
8.5.2 HPV: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

9. Europe Infectious Disease Therapeutics Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Hospital Pharmacies: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview
9.2.2 Retail Pharmacies: Europe Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)

10. Europe Infectious Disease Therapeutics Market – Europe Analysis

10.1 Overview

10.2 Europe

10.2.1 Europe Infectious Disease Therapeutics Market Breakdown, by Key Country, 2023 and 2030 (%)
10.2.1.1 Europe Infectious Disease Therapeutics Market – Revenue and Forecast Analysis – by Country
10.2.1.1 UK: Europe Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.1.1 UK: Europe Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.2.1.1.2 UK: Europe Infectious Disease Therapeutics Market Breakdown, by Indication
10.2.1.1.3 UK: Europe Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.2.1.2 Germany: Europe Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.2.1 Germany: Europe Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.2.1.2.2 Germany: Europe Infectious Disease Therapeutics Market Breakdown, by Indication
10.2.1.2.3 Germany: Europe Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.2.1.3 France: Europe Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.3.1 France: Europe Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.2.1.3.2 France: Europe Infectious Disease Therapeutics Market Breakdown, by Indication
10.2.1.3.3 France: Europe Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.2.1.4 Russia: Europe Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.4.1 Russia: Europe Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.2.1.4.2 Russia: Europe Infectious Disease Therapeutics Market Breakdown, by Indication
10.2.1.4.3 Russia: Europe Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.2.1.5 Italy: Europe Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.5.1 Italy: Europe Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.2.1.5.2 Italy: Europe Infectious Disease Therapeutics Market Breakdown, by Indication
10.2.1.5.3 Italy: Europe Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.2.1.6 Rest of Europe: Europe Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.6.1 Rest of Europe: Europe Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.2.1.6.2 Rest of Europe: Europe Infectious Disease Therapeutics Market Breakdown, by Indication
10.2.1.6.3 Rest of Europe: Europe Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 AbbVie Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Astellas Pharma Inc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Bayer AG

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 BioCryst Pharmaceuticals Inc

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 F. Hoffmann-La Roche Ltd

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Gilead Sciences Inc

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 GSK Plc

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Merck & Co Inc

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Pfizer Inc

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Shionogi & Co Ltd

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

Europe Infectious Disease Therapeutics Market

Analysis - by Drug Class (Anti-viral, Anti Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)